Company intelligence / Profile preview

JucaBio

Ownership: Private
Development stage: Clinical

Overview

JucaBio is a Cincinnati-based biopharma incubator founded in April 2023 by former CinCor Pharma executives. The company raised $3.8 million in seed funding to acquire and develop early-stage novel therapeutics—often dormant or deprioritized by larger firms—and build portfolio companies around them. Its first two known subsidiaries are AllRock (focused on pulmonary hypertension/interstitial lung disease) and AllPrime. The hub-and-spoke model aims to accelerate drug development for high unmet needs. No published clinical results yet.

Therapeutic areas: OtherPulmonologyCardiovascular
Modalities: Not explicitly stated; likely includes small molecules and repurposed therapeutics based on leadership’s history and focus on revitalizing dormant assets
Industry: Biotech

Beyond the preview

Go deeper on JucaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JucaBio.

Explore the full profile